Avalo Therapeutics announced that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. SVB Securities and RBC Capital Markets are acting as joint bookrunning managers for the offering.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AVTX:
- Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
- Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
- Avalo Therapeutics completes target enrollment in Phase 2 PEAK trial
- Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
